1 / 46

Rheumatoid Arthritis Update

Rheumatoid Arthritis Update. Ivonne Herrera, MD Rheumatologist July 20, 2013. Disclosure. Nothing to be disclosed. Outline. Clinical presentation Diagnosis: New diagnostic criteria for RA (2010) Morbidity and Mortality Treatment options. Pierre Auguste Renoir 1841-1919.

makan
Download Presentation

Rheumatoid Arthritis Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rheumatoid Arthritis Update Ivonne Herrera, MD Rheumatologist July 20, 2013

  2. Disclosure • Nothing to be disclosed

  3. Outline • Clinical presentation • Diagnosis: New diagnostic criteria for RA (2010) • Morbidity and Mortality • Treatment options

  4. Pierre Auguste Renoir1841-1919

  5. Rheumatoid Arthritis • Disabling • Destructive • Cause of mortality as well as morbidity

  6. Rheumatoid Arthritis • RA is a symmetric, peripheral polyarthritis of unknown etiology. • If untreated, leads to joint deformity and destruction.

  7. Rheumatoid ArthritisArthritis that affects the MCP and/or PIP joints of both hands, strongly suggests RA

  8. Rheumatoid ArthritisEarly Intermediate Late

  9. Changes in the joint

  10. RA:Laboratory Features • Rheumatoid Factor (RF) • 70-80% RA patients. • Virtually all patients with Mixed Cryoglobulinemia • Sjogren’s Syndrome 70 % • Hepatitis C/B or other chronic infections 50% • SLE 30% • Healthy individuals 5-10% • Anti-CCP: • Similar sensitivity to RF for RA • 95%-98% specificity • Useful to differentiate RA from infections

  11. Other Laboratory Features • Elevated acute phase reactants: • ESR • CRP • Leukocytosis • Thrombocytosis • Anemia of chronic disease • Hypoalbuminemia • ANA + • Inflammatory Synovial Fluid: White cells >2000

  12. Imaging Studies • Plain film radiography • Color Doppler Ultrasonography • MRI

  13. Plain Film Radiography in RA • Soft tissue swelling • Peri-articularosteopenia • Decrease joint space • Bony erosions

  14. Plain Film Radiography in RA MCP and PIP erosions: • 1st year: • 15-30% of patients • 2nd year: • 90% of patients

  15. AtlantoaxialSubluxation in RA

  16. MRI • Allows early detection of: • Synovitis • Bone edema • Erosions • More sensitive and specific than XRays to identify erosions • 4 months: 45% of patients have erosions

  17. Ultrasonography AAAAA

  18. RA Diagnosis: 1987 ACR Criteria • Morning Stiffness: at least 1 hour • Arthritis of 3 or more joints • Arthritis of at least 1 joint in the hand • Symmetric arthritis • Rheumatoid nodules • Serum Rheumatoid Factor (+) • Radiographic changes: erosions RA Diagnosis: 4 out of 7 criteria

  19. 2010 ACR/EULAR Criteria

  20. Differential Diagnosis • Acute viral polyarthritis: • Parvovirus B 19 • Hepatitis B or C • HTLV-1 • CTD: SLE, Sjogren’s, etc • Overlap syndrome • Jaccoud’sarthropathy • Psoriatic arthritis • Gout and Pseudogout • Myelodysplasia • Erosive OA • PMR • Sarcoidosis

  21. RA: Morbidity andPremature Mortality • Cardiovascular Disease • Infections • Lymphoproliferative disorders • Gastrointestinal • Interstitial Lung Disease

  22. CARDIOVASCULAR DISEASE IN RAEPIDEMIOLOGY • RA ↑ risk of premature death. • The risk of CAD mortality was 59 % higher in patients with RA than in the general population (1) • The risk of CAD in RA patients precedes the ACR criteria-based diagnosis of RA (2) Aviña-Zubieta JA, et al, Arthritis Rheum. 2008;59(12):1690. (2) Maradit-Kremers H, et al, Arthritis Rheum. 2005;52(2):402.

  23. RISK OF CVD • DM type II 2-fold increase risk • RA 2.2-fold increase risk

  24. The increase incidence of cardiovascular events in RA patients can not be completely explained by traditional cardiovascular risk factors

  25. CARDIOVASCULAR DISEASE IN RA: PATHOGENESIS • In the general population inflammation has a significant role in the development of CAD • Chronic inflammation in RA may enhance the development of atherosclerosis - Cytokines - Immune complexes - Coagulation abnormalities

  26. Biomarkers for atherosclerosis in patients with RA • ↑ CRP (1) • ↑ESR (2) • ↑IL-6 (3) • ↑TNF α (3) • ↑Von Willebrandfactor, Plasminogen activator inhibitor-1, Fibrinogen (4) • ↓ Endothelial cell progenitors (5) • ↑Ox-LDL-ab (6) • ↑Proinflammatory high-density lipoprotein. (7) Solomon DH, et al, Arthritis Rheum. 2004;50(11):3444. Maradit-KremersH, et al, Arthritis Rheum. 2005;52(3):722. Rho YH, et al, Arthritis Rheum. 2009;61(11):1580 Wållberg-JonssonS, et al, J Rheumatol. 2000;27(1):71. GrisarJ,et al, Circulation. 2005;111(2):204. Peters MJ, J Rheumatol. 2008;35(8):1495. Charles-Schoemanet al, Arthritis Rheum. 2009;60(10):2870

  27. CVD IN RA: PATHOGENESIS • Medications used in RA patients: • Glucocorticoids • Prednisone >7.5mg/day: ↑ MI, CVA, CHF, Mortality • NSAIDs: • Diclofenac • Ibuprofen • Naproxen • COX-2 inhibitors: Celecoxib Risk of MI: ibuprofen ˃Celecoxib ˃diclofenal ˃naproxen Naproxen and Ibuprofen attenuate the antiplatelet effect of aspirin

  28. Traditional Risk Factors for CAD • Hypertention • Smoking • Dyslipidemia • Obesity • Diabetes • Age • Sedentary lifestyle • Family history CAD • Rheumatoid Arthritis..!

  29. RA AS AN INDEPENDENT RISK FACTOR OF CAD • ↑ Prevalence of traditional risk factors (1) • ↑ Prevalence of preclinical atherosclerosis independent of traditional risk factors (2) • Coronary artery calcification on CT scanning is more prevalent in RA patients independent of other CAD risk factors(3) Chung CP, et al, Arthritis Rheum.2005;52(10):3045 Roman MJ, et al, Ann Intern Med. 2006;144(4):249. Kao AH, et all, J Rheumatol. 2008;35(1):61.

  30. Clinical manifestations of CAD in RA patients • ↑ unrecognized MI and sudden cardiac death (1) • Patients with RA are less likely to report chest pain during an acute coronary event (2) Maradit-Kremers H, et all, Arthritis Rheum. 2005;52(2):402 Douglas KM, et all, Ann Rheum Dis. 2006;65(3):348.

  31. Prevention of CHD in RA patients • Smoking cessation • Dyslipidemia control • Healthy diet • Exercise • Weight control • Blood pressure control

  32. Prevention of CHD in RA patients: Early aggressive therapy for RA • MTX is associated with a reduced risk of CVD events in patients with RA (1) • Risk of MI is markedly reduced in those who respond to TNF blockers by 6 months compared with nonresponders (2) • Risk of CVD is lower in patients with RA treated with TNF blockers (3) (1) Westlake SL, et al, Rheumatology (Oxford). 2010;49(2):295. (2) Dixon WG, et al, Arthritis Rheum. 2007;56(9):2905. (3)JacobssonLT, et al, J Rheumatol. 2005;32(7):1213

  33. Early and aggressive therapy in patients with Rheumatoid Arthritis Prevent severe joint destruction and deformities Reduce the risk of CVD and CAD

  34. Treatment Goal in RA • Prevent Joint damage and disability • Prevent Comorbidities • Prevent premature death. • Improve quality of life • Relief symptoms • Achieve clinical REMISSION

  35. Treatment: The Earlier the BetterSharp Score Patients were treated with chloroquine or azathioprine Lard LR, et al. Am J Med. 2001;111:446-451.

  36. Therapeutic Window of Opportunity • Erosive changes occur EARLY in disease • Delay of therapy can have a significant impact • Early DMARD treatment that suppresses the disease appears to reset the rate of progression for years to come O’Dell JR. Arthritis Rheum. 2002;46:283-285. Van derHeijde DM. J Rheum. 1995:34 (suppl 2):74-78.

  37. RA: TREATMENT OPTIONS DMARDs Agents BIOLOGIC Agents Etanercept (ENBREL) Infliximab (REMICADE) Adalimumab (HUMIRA) Golimumab (SIMPONI) Certolizumab (CIMZIA) Anakinra (KINERET) Abatacept (ORENCIA) Rituximab (RITUXAN) Tocilizumab (ACTEMRA) Tofacitinib (XELJANZ) • Prednisone • Methotrexate • Hydroxychloroquine • Sufasalazine • Leflunomide • Cyclosporine • Azathioprine

  38. Several Treatment OptionsWhere should we start? • Methotrexate (MTX) is the most widely used DMARD • SWEFOT *: Monotherapy with MTX • 30% patients responded to initial 3-4months of MTX • 16% in remission • 75% MTX patients maintain low disease activity at 12 months (DAS28<3.2) *Van Vollenhoven RF, et al. Lancet. 2009;374(9688):459-466

  39. Efficacy of Biologic Agents • Efficacy often superior to DMARDs • Rapid onset of action • Well tolerated • Sustained response in many

  40. Evidence Based Medicine with Biologic Agents • The initial use of TNFi or biologic agents with MTX in early RA resulted in significant decreases in radiographic progression in early RA patients (1) • Initial use of TNFi + MTX is more effective clinically than MTX monotherapy in early RA patients (2) • ABA+MTX is more effective clinically and radiographicallythan MTX monotherapy in early RA patients (3) (1)Smolen JS, et al. Lancet. 2007;370(9602):1861-1874) (2)Breedveld FC, et al.Arthritis Rheum.2006;54(1):26-37) (3)Westhovens R, et al.Ann Rheum Dis. 2009;68(12):1870-77

  41. Evidence Based Medicine with Biologic Agents • In patients with early RA who do not achieve LDA with MTX monotherapy, adding a TNFi results in less radiographic progression than adding of non-biologic DMARD(1) • Rituximab is clinically and radiographically effective in TNF-I R patients(2) • Abatacet is clinically effective in TNF-IR patients(3) • Tocilizumab is clinically effective in TNF-IR patients(4) (1)Van Vollenhoven RF, et al. Presented at: 2009 ACR Scientific meeting; October17- 21,2009;Philladelphia, PA. Abstract LB6. (2)Cohen SB, et al. Arthritis Rheum. 2006;54(9):2793-2806. (3)Genovesse MC, et al. Ann Rheum Dis. 2008;67(4):547-554. (4)Emery P, et al. Ann Rheum Dis. 2008;67:1516-1523.

  42. Safety considerations with Biologics • Serious infections • Opportunistic infections (TB) • Malignancies • Demyelination • Hematologic abnormalities • COPD • Administration reactions • CHF • Hepatic impairment • Autoantibodies and Drug induced Lupus • GI perforation • Progressive multifocal leukoencephalopathy

  43. Rheumatoid Arthritis: Summary • Early Diagnosis: Apply the new 2010 Diagnostic criteria for RA • Early aggressive intervention: in patients with RA, critical to best possible outcome • The combination of MTX plus a biologics is frequently more effective than either agent alone • Tight control of traditional risk factors for CAD and early aggressive therapy for RA may reduce the risk of CVD

  44. QUESTIONS Thank you

More Related